Read The Official Patient's Sourcebook on Lupus Online
Authors: MD James N. Parker,PH.D Philip M. Parker
years from the date when the patent application was filed. If the inventor
wishes to receive economic benefits, it is likely that the invention will
become commercially available to patients with lupus nephritis within 20
years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be
commercially available to patients with lupus nephritis. The patent implies
only that the inventor has “the right to exclude others from making, using,
offering for sale, or selling” the invention in the United States. While this
relates to U.S. patents, similar rules govern foreign patents.
In this chapter, we show you how to locate information on patents and their
inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information.
25Adapted from The U. S. Patent and Trademark Office:
http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm
.
74 Lupus Nephritis
Patents on Lupus Nephritis
By performing a patent search focusing on lupus nephritis, you can obtain
information such as the title of the invention, the names of the inventor(s),
the assignee(s) or the company that owns or controls the patent, a short
abstract that summarizes the patent, and a few excerpts from the description
of the patent. The abstract of a patent tends to be more technical in nature,
while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims,
references, figures, diagrams, etc.). We will tell you how to obtain this
information later in the chapter. The following is an example of the type of
information that you can expect to obtain from a patent search on lupus
nephritis:
·
Method for Treatment of Lupus Nephritis
Inventor(s): Clark; William F. (1132 Richmond Street, London, Ontario,
CA), Parbtani; Anwar (418 Rippleton Rd., London, Ontario, CA)
Assignee(s): none reported
Patent Number: 5,837,256
Date filed: December 19, 1996
Abstract: It has been found that by administering secoisolariciresinol ›2,3-
bis(3-methyl-4-hydroxybenzyl)butane-1,4-diol! from flaxseed in
substantially pure form to a human or non-human animal, lupus
nephritis can be controlled. The secoisolariciresinol (Seco) may be used
per se or in the form of secoisolariciresinol diglucoside (SDG). Both
compounds may be extracted from flaxseed and the SDG converts to Seco
in the gut of a human or animal.
Excerpt(s): This invention relates to a method for the treatment of lupus
nephritis. ... Lupus nephritis is considered in medical circles to be the
"classical" auto-immune disease in which the patient's immune system attacks his/her own organs. It has been estimated that 45-75% of lupus
patient's eventually suffer from some form or other of kidney damage.
Lupus varies greatly in severity from mild cases requiring minimal
intervention to those in which significant damage occurs to vital organs
such as lungs, kidneys, heart and brain, and which ultimately can be
fatal. Lupus is predominantly a female disease, an approximate female to
male ratio being 9:1. In North America, it is estimated to affect 1 in 500
female mainly between the age of 20 to 40 years. Treatment is directed at
controlling the symptoms with the hope of putting the disease into
remission. There are several chemotherapeutic agents in commercial use
and available for remedial purposes. Most of these agents are not without
Patents 75
side effects, some of which are severe and debilitating to the patient.
Some non-steroidal anti-inflammatory agents may cause stomach upsets
and changes in kidney function which can mimic some lupus symptoms
themselves. Some anti-malarial drugs, when required at high dosage
levels over prolonged time frame, may accumulate in the retina and
cause loss of vision. Certain steroidal preparations are used for their anti-
inflammatory activity. These can exhibit side effects such as pronounced
swelling of the face and abdomen, weight gain, excessive growth of body
hair, cataracts, osteoporosis and heart attacks. Use of
immunosuppressants can have serious side effects such as changes in
bone marrow, increased risk of infection to which the body normally
shows resistance and a slight increase in the risk of developing certain
types of cancer. There is no known cure for lupus. ... Several reports have
appeared in the scientific and medical literature concerning the ability of
ground flaxseed to act as a mediator in the partial control of Lupus
nephritis. At a level of intake of up to 30 grams per day, ground flaxseed
has been shown to reduce the total cholesterol and LDL cholesterol levels
by 12% and improve renal function in patients with lupus nephritis
›(Clark, Parbtani et al., (1995) Flaxseed: A potential treatment for lupus
nephritis, Kidney International 48: 475-480!. Beyond this intake level, side
effects are evident such as Taxation probably due to increased
fibre/mucilage intake.
Web site: http://www.delphion.com/details?pn=US05837256__
Patent Applications on Lupus Nephritis
As of December 2000, U.S. patent applications are open to public viewing.
26
Applications are patent requests which have yet to be granted (the process to
achieve a patent can take several years).
Keeping Current
In order to stay informed about patents and patent applications dealing with
lupus nephritis, you can access the U.S. Patent Office archive via the Internet at no cost to you. This archive is available at the following Web address:
http://www.uspto.gov/main/patents.htm
. Under “Services,” click on “Search Patents.” You will see two broad options: (1) Patent Grants, and (2) Patent
Applications. To see a list of granted patents, perform the following steps:
Under “Patent Grants,” click “Quick Search.” Then, type “lupus nephritis”
26 This has been a common practice outside the United States prior to December 2000.
76 Lupus Nephritis
(or synonyms) into the “Term 1” box. After clicking on the search button,
scroll down to see the various patents which have been granted to date on
lupus nephritis. You can also use this procedure to view pending patent
applications concerning lupus nephritis. Simply go back to the following
Web address:
http://www.uspto.gov/main/patents.htm
. Under “Services,”
click on “Search Patents.” Select “Quick Search” under “Patent
Applications.” Then proceed with the steps listed above.
Vocabulary Builder
Abdomen:
That portion of the body that lies between the thorax and the pelvis. [NIH]
Cataract:
An opacity, partial or complete, of one or both eyes, on or in the lens or capsule, especially an opacity impairing vision or causing blindness.
The many kinds of cataract are classified by their morphology (size, shape,
location) or etiology (cause and time of occurrence). [EU]
Cholesterol:
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. [NIH]
Immunosuppressant:
An agent capable of suppressing immune responses.
[EU]
Mediator:
An object or substance by which something is mediated, such as (1) a structure of the nervous system that transmits impulses eliciting a
specific response; (2) a chemical substance (transmitter substance) that
induces activity in an excitable tissue, such as nerve or muscle; or (3) a
substance released from cells as the result of the interaction of antigen with antibody or by the action of antigen with a sensitized lymphocyte. [EU]
Osteoporosis:
Reduction in the amount of bone mass, leading to fractures after minimal trauma. [EU]
Retina:
The ten-layered nervous tissue membrane of the eye. It is
continuous with the optic nerve and receives images of external objects and
transmits visual impulses to the brain. Its outer surface is in contact with the choroid and the inner surface with the vitreous body. The outer-most layer is
pigmented, whereas the inner nine layers are transparent. [NIH]
Stomach:
An organ of digestion situated in the left upper quadrant of the abdomen between the termination of the esophagus and the beginning of the
duodenum. [NIH]
Books 77
CHAPTER 6. BOOKS ON LUPUS NEPHRITIS
Overview
This chapter provides bibliographic book references relating to lupus
nephritis. You have many options to locate books on lupus nephritis. The
simplest method is to go to your local bookseller and inquire about titles that they have in stock or can special order for you. Some patients, however, feel
uncomfortable approaching their local booksellers and prefer online sources
(e.g.
www.amazon.com
and
www.bn.com
). In addition to online
booksellers, excellent sources for book titles on lupus nephritis include the
Combined Health Information Database and the National Library of
Medicine. Once you have found a title that interests you, visit your local
public or medical library to see if it is available for loan.
The Combined Health Information Database collects various book abstracts
from a variety of healthcare institutions and federal agencies. To access these summaries, go to
http://chid.nih.gov/detail/detail.html
.
You
will need to use the “Detailed Search” option. To find book summaries, use the drop boxes at
the bottom of the search page where “You may refine your search by.” Select
the dates and language you prefer. For the format option, select
“Monograph/Book.” Now type “lupus nephritis” (or synonyms) into the
“For these words:” box. You will only receive results on books. You should
check back periodically with this database which is updated every 3 months.
The following is a typical result when searching for books on lupus
nephritis:
78 Lupus Nephritis
·
Clinical Nephrology
Source: River Edge, NJ: World Scientific Publishing Co., Inc. 1998. 340 p.
Contact: Available from World Scientific Publishing Co., Inc. 1060 Main
Street, River Edge, NJ 07661. (800) 227-7562 or (201) 487-9655. Fax (888)
977-2665 or (201) 487-9656. E-mail: [email protected]. Website:
www.wspc.com. Price: $15.00 plus shipping and handling. ISBN:
9810234848.
Summary: This book provides a broad review of kidney diseases, with
regard to symptoms, diagnosis, and treatment; the book is designed to
help medical students prepare for their examinations and also to be
useful to practicing physicians who need an overview of kidney disease.
Twenty-seven chapters are included: the structure and function of the
kidneys; symptoms and signs in renal (kidney) medicine; renal
investigations (diagnostic tests); glomerulonephritis (inflammation of the
kidney glomeruli, bundles of filtering units called nephrons); the
nephrotic syndrome (a condition with symptoms of fluid accumulation,
protein in the urine, and susceptibility to infections); the pathogenesis
(development) and treatment of IgA nephritis (kidney inflammation due
to a specific immune system disorder); lupus nephritis (kidney
inflammation due to lupus erythematosus, a systemic inflammatory
disorder); urinary tract infection; sex and the kidney; hypertension (high
blood pressure) and the kidney; diuretics (drugs used to promote the
formation of urine); kidney stones (calculi, nephrolithiasis); diabetes
mellitus and the kidney; fluid and electrolytes; acid base balance; clinical
problems in fluids, electrolytes, and acid base balance; renal tubular
acidosis; renal tubular disorders; systemic disease and the kidney;
pregnancy and the kidney; cancer and the kidney; inherited kidney
diseases; drugs and the kidney; acute renal failure (ARF); chronic renal
failure (CRF); dialysis; and renal transplantation. Each chapter includes
illustrations, tables, answers to common questions, and a list of references
for additional study; a subject index concludes the book.
·
Renal Disease: Classification and Atlas of Glomerular Diseases. 2nd ed
Source: New York, NY: Igaku-Shoin Medical Publishers, Inc. 1995. 541 p.
Contact: Available from Igaku-Shoin. One Madison Avenue, New York,
NY 10010. (800) 765-0800 or (212) 779-0123. Fax (212) 779-0322. Price:
$159.95 (as of 1996). ISBN: 0896402576.
Summary: This atlas of renal diseases has two sections. The first provides
a listing of glomerular lesions and gives their definitions. It also presents
the main clinical and morphological features of glomerular processes in a
tabular format. The second section describes and illustrates the various
Books 79
glomerular processes. Topics include: primary glomerular disease,
including glomerulonephritis; lupus nephritis; IgA nephropathy;
glomerular lesions in systemic bacterial infections; parasitic
glomerulopathies; systemic vasculitis; thrombotic microangiopathy,
including the hemolytic-uremic syndrome and thrombotic
thrombocytopenic purpura; benign nephrosclerosis; diabetic